Class Action Law360 provides breaking news and analysis on class actions and multidistrict litigation. Coverage includes developments in multiparty litigation in federal and state courts, as well as policy issues and court rulings that affect class action procedure.

Sign up for a 7-day FREE trial today!

Latest News in Class Action

• March 13, 2026

  Dorsey Defends Twitter Bot Count In Trial Over Musk Takeover

  Ex-Twitter CEO Jack Dorsey stood by 2022 company statements that bots made up less than 5% of accounts on the platform during video depositions shown Friday in a California federal trial over investor claims that Elon Musk deliberately tanked the company's stock with misstatements about fake accounts to renegotiate the $44 billion deal.

• March 13, 2026

  Child Abuse Material Is Too Easy To Find On Meta, Jury Hears

  Jurors in New Mexico's social media trial saw deposition testimony Friday in which counsel for Meta questioned an expert hired but not called by the state attorney general's office regarding his review of child abuse material on the company's platforms, which he said was "publicly available for anybody."

• March 13, 2026

  Alaska Airlines Pilot's Military Leave Benefits Suit Trimmed

  A Seattle federal judge has narrowed a pilot's class action accusing Alaska Airlines of denying employees sick leave and vacation accrual during military leave, while recognizing in the same Thursday order that a "reasonable jury" could find service members are entitled to certain benefits during absences spanning one to two months.

• March 13, 2026

  DuPont Can't Trim Lead Exposure Case, Judge Advises

  A DuPont company and Hammond Group Inc. shouldn't be allowed to whittle down a proposed class action accusing them of exposing Indiana children to lead for decades, according to a federal magistrate judge's recommendations that rejected arguments that the plaintiffs, who say they have lead in their bones, were not injured.

• March 13, 2026

  Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit

  Neuropsychiatric drugmaker Neumora Therapeutics Inc. seeks to shed investor claims it mischaracterized certain clinical study data ahead of its September 2023 initial public offering, arguing that the trading price decline cited in the complaint was tied to results from a different study that occurred after the IPO.

See more Class Action news